March 12, 2020 / 11:38 AM / 21 days ago

BRIEF-Rubius Therapeutics Q4 Loss Per Share $0.56

Rubius Therapeutics Inc:

* RUBIUS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND ANNOUNCES STRATEGIC FOCUS ON ONCOLOGY AND AUTOIMMUNITY

* Q4 LOSS PER SHARE $0.56

* Q4 EARNINGS PER SHARE ESTIMATE $-0.60 — REFINITIV IBES DATA

* RUBIUS THERAPEUTICS - COMPANY IS DEPRIORITIZING RTX-134 PROGRAM FOR TREATMENT OF PHENYLKETONURIA (PKU) AND ITS OTHER RARE DISEASE PROGRAMS

* CASH RUNWAY WILL BE EXTENDED INTO 2022 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below